ClinicalTrials.gg
TerminatedNCT06679582Updated Oct 13, 2026Results posted

Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML

A Phase 1/2 interventional study of Luveltamab tazevibulin in Acute Myeloid Leukemia (AML), sponsored by Sutro Biopharma, Inc.. Terminated at 36 sites in 9 countries. Open to participants aged 1 Day to 12 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Sutro Biopharma, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Terminated Early
Updated Oct 13, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
1 Day to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States — 309 open to participants now, 463 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
1,823rd of 1,908
1 · median 35
Started
2024
with 70 others
Phase 1/2
306 of 2,138
47 open now
Registered
2,013th of 2,138
by date

Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 1,823rd largest by enrollment of the 1,908 interventional ones that give a count, is one of 71 that started in 2024, is one of 306 in phase 1/2, and was the 2,013th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

309 of the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

304 more — sign in →

All 309 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 1 Day to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children. To be treated in this trial children must have a leukemia which did not respond or recurred after prior treatment. Luveltamab tazevibulin is an antibody-drug conjugate, which brings tazevibulin, an anticancer drug, to a molecule called FOLR1, present on the surface of CBFA2T3::GLIS2 AML cells.

Read the detailed description

This is a registrational international, multicenter, two-part open label Phase 1/2 trial in an extremely rare pediatric disease (around 17 new patients a year in US and 10 in EU). Part 1 randomizes subjects 1:1 to one of two luveltamab tazevibulin dose cohorts (1a and 1b). Part 2 further evaluates the safety and the efficacy of the selected dose. Subjects who achieve complete remission after two cycles of treatment may continue luveltamab tazevibulin as monotherapy, while non-responders at PI discretion may add luveltamab tazevibulin with standard of care (SOC) AML treatments. Luveltamab tazevibulin is given IV every two week as monotherapy and every 4 weeks when given with chemotherapy.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)

Keywords

  • CBFA2T3::GLIS2 Fusion
  • CBFA2T3::GLIS2 AML
  • RAM Phenotype (CD56pos); CD45, CD38, HLA-DR weak or absent)
  • REFRaME
  • AML, Child
  • Pediatric AML
  • REFRaME-P1
  • Luveltamab
  • tazevibulin
  • STRO-002
04

Who can participate

Ages eligible
1 Day to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • AML with CBFA2T3::GLIS2 gene fusion centrally confirmed
  • or relapsed disease with ≥ 5% bone marrow involvement with leukemic blasts by morphology
  • Age \< 12 years.
  • Lansky performance of ≥ 50
  • Adequate organ functions

Exclusion criteria

Exclusion Criteria:

  • Active central nervous system (CNS) disease (CNS3)
  • Pre-existing corneal disorders or constitutional diseases associated with an increased risk of AML treatment toxicities
  • Active or uncontrolled infections or other active severe intercurrent illnesses,
  • Prior treatment with a FOLR1- targeting ADCs or with ADCs that contain a tubulin inhibitor
  • History of hematopoietic stem cell transplant or any organ transplant in the prior 84 days
  • (GVHD) of any grade or GVHD treatment with exception of low dose
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Cohort 1

    Luveltamab tazevibulin 3.5mg every 2 weeks

    Drug: Luveltamab tazevibulin

  • Experimental
    Cohort 2

    Luveltamab tazevibulin 4.3 mg every 2 weeks

    Drug: Luveltamab tazevibulin

Interventions

  • Luveltamab tazevibulin is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα or FOLR1). It consists of an IgG1 antibody (SP8166) conjugated to cathepsin cleavable 3-aminophenyl hemiasterlin payload, yielding a homogenous ADC with a drug antibody ratio of four. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death. Other Names: * STRO-002 * Luvelta

    Also known as: STRO-002, Luvelta

06

What researchers measure

Primary outcomes

  1. Evaluate Efficacy of Luveltamab Tazevibulin Monotherapy

    Complete remission rate

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Evaluate Safety Measures

    Incidence and severity of AEs and clinical laboratory abnormalities per NCI CTCAE v5.0 in patients receiving luveltamab tazevibulin monotherapy.

    Time frame: Up to 2 years

  2. To Characterize the PK of Luveltamab Tazevibulin

    Concentration of luveltamab tazevibulin (ADC, TAb, and SC209) in the blood.

    Time frame: Up to 2 years

  3. Assess the Immunogenic Potential of Luveltamab Tazevibulin

    Incidence of ADAs

    Time frame: Up to 2 years

  4. Assess Additional Efficacy Outcome Measures

    • Response rate including complete remission with partial hematologic recovery (CRh) rate \[CR = CRh\]

    Time frame: Up to 2 years

  5. Assess Additional Efficacy Outcome Measures

    • Event-free survival (EFS)

    Time frame: Up to 2 years

  6. Assess Additional Efficacy Outcome Measures

    • Relapse-free survival (RFS)

    Time frame: Up to 2 years

  7. Assess Additional Efficacy Outcome Measures

    • Overall survival (OS)

    Time frame: Up to 2 years

  8. Assess Additional Efficacy Outcome Measures

    Duration of CR

    Time frame: Up to 2 years

07

Results

Posted Oct 13, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2
Started10
Completed00
Not completed10

Outcome measures

PrimaryEvaluate Efficacy of Luveltamab Tazevibulin Monotherapy

Complete remission rate

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants

No measurements were reported for this outcome.

SecondaryEvaluate Safety Measures

Incidence and severity of AEs and clinical laboratory abnormalities per NCI CTCAE v5.0 in patients receiving luveltamab tazevibulin monotherapy.

Time frame:
Up to 2 years
Reported as:
Number

No measurements were reported for this outcome.

SecondaryTo Characterize the PK of Luveltamab Tazevibulin

Concentration of luveltamab tazevibulin (ADC, TAb, and SC209) in the blood.

Time frame:
Up to 2 years
Reported as:
Number

No measurements were reported for this outcome.

SecondaryAssess the Immunogenic Potential of Luveltamab Tazevibulin

Incidence of ADAs

Time frame:
Up to 2 years
Reported as:
Number

No measurements were reported for this outcome.

SecondaryAssess Additional Efficacy Outcome Measures

• Response rate including complete remission with partial hematologic recovery (CRh) rate \[CR = CRh\]

Time frame:
Up to 2 years
Reported as:
Number

No measurements were reported for this outcome.

SecondaryAssess Additional Efficacy Outcome Measures

• Event-free survival (EFS)

Time frame:
Up to 2 years
Reported as:
Number

No measurements were reported for this outcome.

SecondaryAssess Additional Efficacy Outcome Measures

• Relapse-free survival (RFS)

Time frame:
Up to 2 years
Reported as:
Number

No measurements were reported for this outcome.

SecondaryAssess Additional Efficacy Outcome Measures

• Overall survival (OS)

Time frame:
Up to 2 years
Reported as:
Number

No measurements were reported for this outcome.

SecondaryAssess Additional Efficacy Outcome Measures

Duration of CR

Time frame:
Up to 2 years
Reported as:
Number

No measurements were reported for this outcome.

Adverse events

Collected over 5.9 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/1 (0%)0/1 (0%)1/1 (100%)
Cohort 2———
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCohort 1Cohort 2
VomitingGastrointestinal disorders1/1—
RhinorrheaRespiratory, thoracic and mediastinal disorders1/1—
Nasal CongestionRespiratory, thoracic and mediastinal disorders1/1—
PruritusSkin and subcutaneous tissue disorders1/1—
Procedural PainInjury, poisoning and procedural complications1/1—
Puncture site painGeneral disorders1/1—
Platelet cout decreasedInvestigations1/1—
AnaemiaBlood and lymphatic system disorders1/1—
Aspartate aminotransferase increasedInvestigations1/1—
Alanine aminotransferase increasedInvestigations1/1—

Baseline characteristics

Only 1 participant was enrolled and was assigned to Cohort 1

Age, Continuous
Age, Continuous(Years)Cohort 1Cohort 2Total
Mean1—1
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female101
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101
More than one race000
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Total
Hispanic or Latino000
Not Hispanic or Latino101
Unknown or Not Reported000
08

Study locations

36 sites
  • Childrens Hospital of Alabama
    Birmingham, Alabama 35233, United States
  • Childrens Hospital of Los Angeles
    Los Angeles, California 90027, United States
  • Lucile Packard Childrens Hospital-Stanford
    Palo Alto, California 94304, United States
  • Children's Hospital of Colorado
    Aurora, Colorado 80045, United States
  • Childrens National Hospital
    Washington D.C., District of Columbia 20010, United States
  • Children's Hospital of Atlanta-Emory
    Atlanta, Georgia 30322, United States
  • Ann & Robert H. Lurie Childrens Hospital
    Chicago, Illinois 60611, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Minnesota-Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Washington University-School of Medicine
    St Louis, Missouri 63110, United States
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
  • Duke University Medical Center
    Durham, North Carolina 27711, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
  • Baylor College of Medicine-Dan Duncan Comprehensive Cancer Center
    Houston, Texas 77030, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Massey Cancer Center-Adult Outpatient Pavillion
    Richmond, Virginia 23219, United States
  • Seattle Childrens
    Seattle, Washington 98105, United States
  • St Anna Kinderspital
    Vienna, 1090, Austria
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • Centre Hospitalier Universitaire-Sainte Justice
    Montreal, Quebec H3T 1C5, Canada
  • Rigshopitalet-University of Copenhagen
    Copenhagen, 02100, Denmark
  • Institut d'hématologie et d'oncologie pédiatrique
    Lyon, 69008, France
  • Hopital Armand Trousseau
    Paris, 75012, France
  • Charite-Universitatsmedizin Berlin
    Berlin, 13353, Germany
  • Universitatsklinikum-Essen
    Essen, 45122, Germany
  • Fondazione IRCCS San Gerardo dei Tintori
    Monza, 20900, Italy
  • Children Hospital Bambino Gesu IRCCS
    Rome, 00165, Italy
  • Princess Maxima Center for Pediatric Oncology
    CS Utrecht, 3584, Netherlands
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Infantil Universitario Nino Jesus-Servicio de Hematologia
    Madrid, 28009, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2024 to primary completion in Jan 2025, 1 month.

Results were first posted in Oct 2026, 1 year 8 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jun 2025 → Jan 2025 and completion Jun 2025 → Jan 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2024
First posted
Nov 7, 2024
StartActual
Dec 4, 2024
Primary completionActual
Jan 21, 2025was Jun 2025
CompletionActual
Jan 21, 2025was Jun 2025
Results first posted
Oct 13, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 13, 2026
Primary completion
Jun 1, 2025→Jan 21, 2025
Oct 13, 2026
Study completion
Jun 1, 2025→Jan 21, 2025
Oct 13, 2026
Enrollment
24→1
Oct 13, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedEvaluate efficacyEfficacy of luveltamab tazevibulin monotherapyLuveltamab Tazevibulin MonotherapyTime frame: Up to 12 weeks
Oct 13, 2026
Documents
Secondary outcomes
8 edited
What changed in the outcomes
  • EditedAssess additional efficacy outcome measuresAdditional Efficacy Outcome MeasuresTime frame: Up to 2 years
  • EditedEvaluate safety measuresSafety MeasuresTime frame: Up to 2 years
  • EditedTo characterizeCharacterize the PK of luveltamab tazevibulinLuveltamab TazevibulinTime frame: Up to 2 years
  • EditedAssess the immunogenic potentialImmunogenic Potential of luveltamab tazevibulinLuveltamab TazevibulinTime frame: Up to 2 years
  • EditedAssess additional efficacy outcome measuresAdditional Efficacy Outcome MeasuresTime frame: Up to 2 years
  • EditedAssess additional efficacy outcome measuresAdditional Efficacy Outcome MeasuresTime frame: Up to 2 years
  • EditedAssess additional efficacy outcome measuresAdditional Efficacy Outcome MeasuresTime frame: Up to 2 years
  • EditedAssess additional efficacy outcome measuresAdditional Efficacy Outcome MeasuresTime frame: Up to 2 years
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Results posted
    Primary completion Jun 1, 2025→Jan 21, 2025
    Study completion Jun 1, 2025→Jan 21, 2025
    Enrollment 24→1
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedEvaluate efficacyEfficacy of luveltamab tazevibulin monotherapyLuveltamab Tazevibulin MonotherapyTime frame: Up to 12 weeks
    Secondary outcomes 8 edited
    What changed in the outcomes
    • EditedAssess additional efficacy outcome measuresAdditional Efficacy Outcome MeasuresTime frame: Up to 2 years
    • EditedEvaluate safety measuresSafety MeasuresTime frame: Up to 2 years
    • EditedTo characterizeCharacterize the PK of luveltamab tazevibulinLuveltamab TazevibulinTime frame: Up to 2 years
    • EditedAssess the immunogenic potentialImmunogenic Potential of luveltamab tazevibulinLuveltamab TazevibulinTime frame: Up to 2 years
    • EditedAssess additional efficacy outcome measuresAdditional Efficacy Outcome MeasuresTime frame: Up to 2 years
    • EditedAssess additional efficacy outcome measuresAdditional Efficacy Outcome MeasuresTime frame: Up to 2 years
    • EditedAssess additional efficacy outcome measuresAdditional Efficacy Outcome MeasuresTime frame: Up to 2 years
    • EditedAssess additional efficacy outcome measuresAdditional Efficacy Outcome MeasuresTime frame: Up to 2 years
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06679582
Lead sponsor
Sutro Biopharma, Inc.
Collaborators
Children's Oncology Group, Innovative Therapies For Children with Cancer Consortium
Responsible party
Sponsor
First posted
Nov 7, 2024
Start date
Dec 4, 2024
Primary completion
Jan 21, 2025
Completion
Jan 21, 2025
Results posted
Oct 13, 2026
Last update
Oct 13, 2026

Study contacts

Craig Berman, MD
study director · Sutro Biopharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luveltamab tazevibulin

Start the discussion